These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 30127394)

  • 21. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
    Gauci ML; Boudou P; Baroudjian B; Vidal-Trecan T; Da Meda L; Madelaine-Chambrin I; Basset-Seguin N; Bagot M; Pages C; Mourah S; Resche-Rigon M; Pinel S; Sassier M; Rouby F; Eftekhari P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is earlier better for melanoma checkpoint blockade?
    Robert C
    Nat Med; 2018 Nov; 24(11):1645-1648. PubMed ID: 30401867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
    Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
    Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
    Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
    Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
    Elia AR; Caputo S; Bellone M
    Front Immunol; 2018; 9():1786. PubMed ID: 30108594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
    Sheng Y; Tong L; Geyu L
    Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1, CTLA-4 Point to Drug Response.
    Cancer Discov; 2016 Nov; 6(11):1201. PubMed ID: 27655434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
    Zhao B; Zhao H; Zhao J
    Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.
    Buchbinder EI; Hodi FS
    Nat Rev Clin Oncol; 2016 Feb; 13(2):77-8. PubMed ID: 26787285
    [No Abstract]   [Full Text] [Related]  

  • 34. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
    Goltz D; Gevensleben H; Vogt TJ; Dietrich J; Golletz C; Bootz F; Kristiansen G; Landsberg J; Dietrich D
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
    Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
    J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
    Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.